<?xml version='1.0' encoding='utf-8'?>
<document id="27162627"><sentence text="Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam."><entity charOffset="46-58" id="DDI-PubMed.27162627.s1.e0" text="ketoconazole" /><entity charOffset="60-74" id="DDI-PubMed.27162627.s1.e1" text="clarithromycin" /><entity charOffset="80-89" id="DDI-PubMed.27162627.s1.e2" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.27162627.s1.e0" e2="DDI-PubMed.27162627.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27162627.s1.e0" e2="DDI-PubMed.27162627.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27162627.s1.e0" e2="DDI-PubMed.27162627.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27162627.s1.e1" e2="DDI-PubMed.27162627.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27162627.s1.e1" e2="DDI-PubMed.27162627.s1.e2" /></sentence><sentence text="Riociguat is a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension that is principally metabolized via the cytochrome P450 (CYP) pathway" /><sentence text=" Three studies in healthy males investigated potential pharmacokinetic interactions between riociguat and CYP inhibitors (ketoconazole, clarithromycin, and midazolam)"><entity charOffset="122-134" id="DDI-PubMed.27162627.s3.e0" text="ketoconazole" /><entity charOffset="136-150" id="DDI-PubMed.27162627.s3.e1" text="clarithromycin" /><entity charOffset="156-165" id="DDI-PubMed.27162627.s3.e2" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.27162627.s3.e0" e2="DDI-PubMed.27162627.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27162627.s3.e0" e2="DDI-PubMed.27162627.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27162627.s3.e0" e2="DDI-PubMed.27162627.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27162627.s3.e1" e2="DDI-PubMed.27162627.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27162627.s3.e1" e2="DDI-PubMed.27162627.s3.e2" /></sentence><sentence text=" In two studies, subjects were pretreated with either once-daily ketoconazole 400 mg or twice-daily clarithromycin 500 mg for 4 days before cotreatment with either riociguat 0"><entity charOffset="65-77" id="DDI-PubMed.27162627.s4.e0" text="ketoconazole" /><entity charOffset="100-114" id="DDI-PubMed.27162627.s4.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.27162627.s4.e0" e2="DDI-PubMed.27162627.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27162627.s4.e0" e2="DDI-PubMed.27162627.s4.e1" /></sentence><sentence text="5 mg ± ketoconazole 400 mg or riociguat 1" /><sentence text="0 mg ± clarithromycin 500 mg"><entity charOffset="7-21" id="DDI-PubMed.27162627.s6.e0" text="clarithromycin" /></sentence><sentence text=" In the third study, subjects received riociguat 2" /><sentence text="5 mg 3 times daily (tid) for 3 days, followed by cotreatment with riociguat 2" /><sentence text="5 mg tid ± midazolam 7" /><sentence text="5 mg" /><sentence text=" Pharmacokinetic parameters, the effect of smoking on riociguat pharmacokinetics, safety, and tolerability were assessed" /><sentence text=" Pre- and cotreatment with ketoconazole and clarithromycin led to increased riociguat exposure"><entity charOffset="27-39" id="DDI-PubMed.27162627.s12.e0" text="ketoconazole" /><entity charOffset="44-58" id="DDI-PubMed.27162627.s12.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.27162627.s12.e0" e2="DDI-PubMed.27162627.s12.e0" /><pair ddi="false" e1="DDI-PubMed.27162627.s12.e0" e2="DDI-PubMed.27162627.s12.e1" /></sentence><sentence text=" Pre- and cotreatment with riociguat had no significant effect on midazolam plasma concentrations" /><sentence text=" In all studies, the bioavailability of riociguat was reduced in smokers because its clearance to the metabolite M1 increased" /><sentence text=" Riociguat ± ketoconazole, clarithromycin, or midazolam was generally well tolerated"><entity charOffset="13-25" id="DDI-PubMed.27162627.s15.e0" text="ketoconazole" /><entity charOffset="27-41" id="DDI-PubMed.27162627.s15.e1" text="clarithromycin" /><entity charOffset="46-55" id="DDI-PubMed.27162627.s15.e2" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.27162627.s15.e0" e2="DDI-PubMed.27162627.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27162627.s15.e0" e2="DDI-PubMed.27162627.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27162627.s15.e0" e2="DDI-PubMed.27162627.s15.e2" /><pair ddi="false" e1="DDI-PubMed.27162627.s15.e1" e2="DDI-PubMed.27162627.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27162627.s15.e1" e2="DDI-PubMed.27162627.s15.e2" /></sentence><sentence text=" The most common treatment-emergent adverse events (TEAEs) across all studies were headache and dyspepsia" /><sentence text=" One serious TEAE was reported in the midazolam study"><entity charOffset="38-47" id="DDI-PubMed.27162627.s17.e0" text="midazolam" /></sentence><sentence text=" Owing to the potential for hypotension, concomitant use of riociguat with multipathway inhibitors, such as ketoconazole, should be approached with caution"><entity charOffset="108-120" id="DDI-PubMed.27162627.s18.e0" text="ketoconazole" /></sentence><sentence text=" Coadministration of riociguat with strong CYP3A4 inhibitors, for example, clarithromycin, does not require additional dose adjustment"><entity charOffset="75-89" id="DDI-PubMed.27162627.s19.e0" text="clarithromycin" /></sentence><sentence text=" No significant drug-drug interaction was revealed between riociguat and midazolam" /><sentence text=" " /></document>